Clinical Focus

Previous Articles     Next Articles

Clinical study of calcium dibutyryladenosine cyclophosphate in prevention of  subacute cardiotoxicity induced by doxorubicin chemotherapy

  

  1. Department of Integrated Traditional and Western Medicine, the People’s Hospital
    of Qingyang, Qingyang 745000, China
  • Online:2017-12-05 Published:2017-12-14
  • Contact: Corresponding author: Miao Yandong, Email: miaoyandong11@126.com

Abstract: Objective  To observe the protective effect of calcium dibutyryladenosine cyclophosphate in subacute cardiotoxicity induced by doxorubicin chemotherapy. Methods  Totally 47 cases of breast cancer and lymphoma were randomly divided into control group(n=23)  and treatment group(n=24).  Both groups received the chemotherapy regimens containing doxorubicin and the treatment group had an addition injection of calcium dibutyryladenosine cyclophosphate. Both groups received four complete cycles of chemotherapy. The ECG changes, echocardiography (left ventricular ejection fraction, LVEF), Nterminal probrain natriuretic peptide (NTproBNP), cardiac troponin I (cTnI) and CKMB values in both groups were observed before the chemotherapy and after two and four cycle chemotherapy.Results  Upon comparing the ECG changes, LVEF, cTnI, NTproBNP and CKMB values of both groups before 48 hours of the chemotherapy and after one week of two and four cycle chemotherapy, treatment group had lesser incidence rates in abnormal ECG, decreased LVEF, increased cTnI, NTproBNP and CKMB (P<0.05). Conclusion  Calcium dibutyryladenosine cyclophosphate may reduce the cardiotoxicity induced by doxorubicin chemotherapy.

Key words: breast neoplasms, lymphoma, cardiotoxins, doxorubicin, calcium dibutyryladenosini cyclophosphas